Dayvigo Manufacturer Bridge Programs: How to Get Lemborexant Cheaper in 2026

What Is Dayvigo and Why Does Cost Matter?

Dayvigo (lemborexant) is a dual orexin receptor antagonist approved by the FDA on December 20, 2019, for the treatment of insomnia characterized by difficulties with sleep onset or sleep maintenance in adults. [1] Unlike older benzodiazepine-class hypnotics, lemborexant blocks the wake-promoting orexin neuropeptide system rather than broadly suppressing the central nervous system.

The key SUNRISE-1 trial (N=291) demonstrated that lemborexant 5 mg and 10 mg both produced statistically significant reductions in subjective sleep onset latency compared with placebo at one month, and the 12-month SUNRISE-2 trial (N=949) confirmed durable efficacy without evidence of tolerance. [2][3] The drug's clinical profile positions it as a preferred option for many patients with chronic insomnia disorder, which the American Academy of Sleep Medicine defines as occurring at least three nights per week for at least three months. [4]

The problem is price. Without insurance, a 30-tablet supply of Dayvigo costs roughly $480 to $540 at U.S. Retail pharmacies as of early 2026. That figure makes long-term adherence financially difficult for a large segment of patients, particularly those on high-deductible health plans or those whose formularies place lemborexant on a Tier 3 or Tier 4 specialty rung.

Chronic insomnia disorder affects an estimated 10 to 15 percent of U.S. Adults, according to data published in Sleep Medicine Reviews. [5] Given the size of that population and the cost burden of branded DORAs, understanding every available savings mechanism is a practical clinical necessity.

Eisai's Co-Pay Savings Card: The Primary Bridge Program

How the Card Works

Eisai's Dayvigo Co-Pay Savings Card is the manufacturer's front-line bridge tool for commercially insured patients. Enrolled patients pay as little as $0 per monthly fill, with the card covering the gap between their insurance cost-sharing obligation and the program cap. Eisai sets the maximum benefit at approximately $150 per fill, though the program terms are reviewed at least annually and may change mid-year.

The card is processed like a secondary insurance coupon at the point of sale. The patient presents both their primary insurance card and the savings card; the pharmacy adjudicates insurance first, then applies the manufacturer discount to the remaining balance.

Eligibility Criteria

To qualify for the co-pay card, a patient must meet all of the following conditions:

• Have a valid prescription for Dayvigo written by a licensed U.S. Prescriber.
• Be covered by a commercial (private) insurance plan. Medicare, Medicaid, TRICARE, and other federal or state government-funded plans are explicitly excluded by law under the federal Anti-Kickback Statute. [6]
• Be a U.S. Resident aged 18 or older.
• Not be enrolled in any state or federal pharmaceutical assistance program.

Age restriction matters here: lemborexant's FDA label does not include a pediatric indication, and the co-pay card mirrors that by limiting enrollment to adults. [1]

Enrollment Steps

1. Ask your prescriber or pharmacist for the Eisai Dayvigo savings card enrollment form, or download it directly from the Eisai U.S. Patient support portal (eisai.us).
2. Complete the one-page form with your name, date of birth, insurance information, and prescriber's NPI number.
3. Present the card at any participating retail or mail-order pharmacy.
4. No income verification is required for the co-pay card. The only verification is insurance eligibility.

Activation is typically instant at the pharmacy counter. If the card is rejected, the most common reason is a government-payer flag in the adjudication system.

Eisai Patient Assistance Program (PAP): For Uninsured and Underinsured Patients

Who the PAP Serves

Patients without any prescription drug coverage, or whose coverage provides no benefit for Dayvigo at any tier, may qualify for Eisai's Patient Assistance Program. The PAP provides Dayvigo at no charge for the duration of eligibility.

A 2022 analysis in the Journal of Managed Care and Specialty Pharmacy found that manufacturer PAPs reach a meaningfully different demographic than co-pay cards, primarily uninsured patients under 65 and those whose insurers have issued a prior authorization denial. [7] Lemborexant's PAP follows that pattern.

Income and Insurance Thresholds

Eisai's PAP uses income-to-federal-poverty-level ratios as its primary filter. As of early 2026:

• Household income at or below 400% of the Federal Poverty Level (FPL) generally qualifies for full free product.
• Patients between 400% and 600% FPL may qualify for a reduced-cost tier, Eisai reviews these cases individually.
• Patients above 600% FPL are typically ineligible for the PAP but may still use the co-pay card if commercially insured.

The 2026 FPL for a single-person household is $15,060; 400% equals $60,240. For a family of four, 400% FPL equals approximately $124,800. [8]

PAP Enrollment Process

1. Obtain a completed PAP application from Eisai's patient support line (1-888-DAYVIGO or the Eisai Patient Assistance portal).
2. Submit proof of income (most recent federal tax return or three months of pay stubs) and proof of insurance status.
3. Have the prescriber complete the clinical section of the form, including diagnosis (ICD-10: G47.00 for insomnia, unspecified) and the intended duration of therapy.
4. Eisai's program team typically responds within 5 to 10 business days. Approved patients receive a 90-day supply mailed directly to their home or to the prescriber's office, depending on state regulations.
5. Renewal is required every 12 months with updated income documentation.

Prior Authorization Challenges and How to Overcome Them

Why PA Denials Happen for Lemborexant

Most commercial and Medicare Part D plans require prior authorization before covering Dayvigo. The standard formulary rationale is step therapy: the plan wants evidence that the patient has tried and failed at least one generic hypnotic, most commonly zolpidem or trazodone, before approving a branded DORA.

The FDA's label for Dayvigo does not mandate step therapy, but payer policies are independent of the label. [1] A 2023 review in JAMA Internal Medicine noted that step-therapy requirements for sleep medications disproportionately delay care for patients whose comorbidities (substance use history, parasomnias, REM sleep behavior disorder) make older agents less appropriate. [9]

Building a Strong PA Appeal

If the initial PA is denied, the prescriber can file a medical necessity appeal using the following evidence base:

• Documented treatment failure or contraindication with at least one first-line generic (e.g., zolpidem, eszopiclone, or doxepin).
• A sleep study result or validated screening tool score, such as the Insomnia Severity Index (ISI), showing moderate-to-severe disease burden. [10]
• A letter of medical necessity citing SUNRISE-2 (N=949) data showing maintained efficacy at 12 months without rebound insomnia on discontinuation. [3]
• Any comorbidity that makes benzodiazepine-receptor agonists higher risk: history of substance use disorder, concurrent opioid use, documented sleepwalking, or age 65+ (older adults face elevated fall risk with zolpidem per the 2023 Beers Criteria). [11]

The American Academy of Sleep Medicine's 2017 clinical practice guideline on chronic insomnia provides direct prescriber-quotable language supporting lemborexant-class agents. [4] Appeals citing named guidelines carry more weight than appeals based on clinical opinion alone.

What to Do While the Appeal Is Pending

The co-pay savings card does not require prior authorization to activate. If the PA process will take more than a week, have the prescriber write the prescription, submit it under cash pay, and apply the co-pay card immediately. The patient pays the discounted cash price. Once the PA is approved, the patient transitions to insurance billing with the card covering remaining cost-sharing.

Third-Party Discount Programs and Pharmacy Coupons

GoodRx, RxSaver, and Similar Platforms

Third-party pharmacy discount platforms negotiate contracted rates with pharmacy chains. For lemborexant, GoodRx prices as of early 2026 range from approximately $380 to $490 for 30 tablets at major chains, representing a 10 to 20 percent reduction from the sticker cash price. These discounts cannot be combined with insurance, using a GoodRx coupon means the transaction is processed entirely as cash, with no insurance adjudication.

Patients using these platforms should be aware that cash-pay transactions typically do not count toward insurance deductibles. A brief summary published by the National Academy for State Health Policy confirms that most state insurance commissioners have declined to require insurers to count coupon-assisted purchases toward deductibles. [12]

340B Program Access

Patients who receive their care at a federally qualified health center (FQHC), qualifying hospital outpatient department, or other 340B-covered entity may access Dayvigo at the 340B ceiling price, which the Health Resources and Services Administration (HRSA) sets below average manufacturer price. [13] Patients do not apply for 340B directly; the covered entity purchases the drug at the reduced price and may pass savings to patients through lower co-pays.

Patients in rural or underserved areas should ask their prescriber whether their clinic participates in the 340B program before exploring other options.

Medicare and Medicaid Coverage Pathways

Medicare Part D

Lemborexant is covered under Medicare Part D, but formulary placement varies widely by plan. In 2025 CMS formulary data, approximately 60 percent of stand-alone Part D plans listed Dayvigo on Tier 3 or higher, requiring prior authorization and step therapy. [14] The Inflation Reduction Act's $2,000 out-of-pocket cap for Part D took effect in 2025, which meaningfully limits total annual exposure for Medicare beneficiaries, though it does not eliminate monthly cost-sharing.

Medicare beneficiaries are not eligible for Eisai's co-pay card. The Extra Help (Low Income Subsidy) program through the Social Security Administration is the primary manufacturer-independent assistance pathway for this population. [15]

Medicaid

Medicaid coverage for Dayvigo varies by state. Because lemborexant is a Schedule IV controlled substance, some state Medicaid programs require quantity limits and prior authorization. Patients on Medicaid who are denied coverage should ask their prescriber to submit a Medicaid prior authorization with the same medical necessity documentation described above.

HSA and FSA Eligibility for Dayvigo

Dayvigo is eligible for payment via Health Savings Account (HSA) or Flexible Spending Account (FSA) funds, provided the patient holds a valid prescription. The IRS defines eligible medical expenses in Publication 502, which includes prescription medications. [16] Because lemborexant is a Schedule IV controlled substance, it requires a written prescription in all 50 states, that prescription simultaneously satisfies the IRS requirement for HSA/FSA eligibility.

Practical points:

• Use your HSA or FSA debit card at the pharmacy counter. No special pre-authorization with the account administrator is required.
• If you pay out of pocket and want reimbursement, retain the pharmacy receipt showing the drug name, quantity, and prescriber information.
• HSA funds roll over indefinitely; FSA funds are typically subject to a use-it-or-lose-it rule, though many plans allow a $640 rollover (2026 IRS limit) or a 2.5-month grace period. [16]

Combining an HSA/FSA payment with the Eisai co-pay card is permitted: apply the co-pay card first to reduce the amount charged, then pay the remaining balance (if any) with HSA/FSA funds.

Stacking Savings: The Optimal Sequence for 2026

Not every savings tool can be combined, but a deliberate sequence maximizes value:

Commercially insured patients:

1. Submit the prescription to insurance. If Dayvigo is covered (even at a high tier), use the Eisai co-pay card to offset the cost-sharing amount, up to the $150/fill card cap.
2. Pay any residual balance with HSA or FSA funds.
3. If PA is required, file promptly and use the cash-pay plus co-pay-card bridge in the interim.

Uninsured patients:

1. Apply for the Eisai PAP. If income qualifies, receive the drug at no charge.
2. While the PAP application is under review (5 to 10 business days), use a third-party discount card (GoodRx or equivalent) to reduce the cash price on an initial fill.
3. If PAP income threshold is not met, explore whether a 340B-participating clinic is accessible.

Medicare beneficiaries:

1. Apply for Extra Help through SSA if income and assets qualify. Extra Help can reduce Part D cost-sharing to a few dollars per fill. [15]
2. If denied Extra Help, consider switching to a Part D plan with more favorable Dayvigo tier placement during the annual open enrollment period (October 15 to December 7).

Safety Context: Why Correct Dosing Matters for Cost Planning

Cost planning intersects directly with dosing. Lemborexant is available in 5 mg and 10 mg strengths. The FDA-approved starting dose is 5 mg; the label recommends not exceeding 10 mg per night. [1] Because both strengths carry the same retail price per tablet, a patient who starts at 5 mg and later requires 10 mg doubles their monthly pill count and their monthly cost.

Clinicians prescribing lemborexant should counsel patients on this arithmetic early. Starting at 5 mg and reassessing at 4 weeks aligns with both the label's titration guidance and the SUNRISE-1 efficacy data showing comparable sleep-onset benefit at 5 mg versus 10 mg in most patients. [2] Keeping the dose at 5 mg where efficacious can cut annual drug expenditure by approximately 50 percent.

The FDA's label also notes that CNS depressant effects persist for up to several hours after administration; patients should be warned not to drive until fully awake. [1] This is not merely a safety note, it affects scheduling for patients who work early shifts and may influence adherence if not addressed proactively.

Frequently Asked Questions